Evidence map›Paper›PMID 31938021›Full record

ArticleCancer cell international2020

Over-expression of CDX2 alleviates breast cancer by up-regulating microRNA let-7b and inhibiting COL11A1 expression.

Hongbin Wang, Yanlv Ren, Cheng Qian, Jiaxin Liu, Ge Li, Zhigao Li

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Dynamic Changes of Gene Expression in Mouse Mural Trophectoderm Regulated byFrontiers in cell and developmental biology · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Collagen XI alpha 1 chain, a potential therapeutic target for cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hongbin Wang *Department of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Yanlv Ren *Department of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Cheng QianDepartment of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Jiaxin LiuDepartment of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Ge LiDepartment of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Zhigao LiDepartment of Breast Surgery (No. 2 Sickroom), Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmicroRNA Let-7 serves as a tumor suppressor by targeting various oncogenic pathways in cancer cells. However, the underlying mechanism of its involvement in breast cancer remains largely unknown. With our research, our endeavor is to explore the role of the CDX2/let-7b/COL11A1 axis in breast cancer cell activities.

methodsTumor tissues and adjacent normal tissues were collected from 86 patients with breast cancer. Human breast cancer epithelial cell line MCF-7 was treated with over-expressed CDX2, let-7b mimic, shRNA against COL11A1 and their negative controls. The expression of CDX2, let-7b, and COL11A1 in the tissues and cells was determined by RT-qPCR. Interactions among CDX2, let-7b, and COL11A1 were detected by ChIP and dual-luciferase reporter assay, respectively. After different transfections, cell invasion, migration, and proliferation abilities were determined by Transwell and EdU assays. Lastly, tumor xenografts in nude mice were established and hematoxylin and eosin staining was performed to assess the tumor growth and lymph node metastasis.

resultsCDX2 and let-7b were poorly expressed in breast cancer cells and tissues. CDX2 bound to let-7b and promoted the expression of let-7b, which contrarily inhibited the expression of COL11A1. Cancer cell proliferation, invasion, migration, and metastasis were stimulated when CDX2 and let-7b were depleted or COL11A1 was over-expressed. Xenograft tumors growth and metastasis were in accordance with the results of cellular experiments.

conclusionIn agreement with these observations, we could reach a conclusion that CDX2 could promote let-7b expression, which may exert an inhibitory effect on the proliferation, migration, and metastasis of breast cancer cells via repressing the expression of COL11A1, providing a novel therapeutic strategy for the treatment of metastatic breast cancer.

Indexed as

Breast cancerCDX2COL11A1Invasionlet-7bMigration

Identifiers

PMID31938021
PMCPMC6954621
OpenAlexW2999699293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.